Skip to content

Study · Animal study (in vivo) · mouse · 2025

14 results

Intranasal pramlintide matches intraperitoneal effects on food intake and gastric emptying in mice.

Almeida MS, Sanches MP, Tonet NS, Zuglianello C, Morari J, Velloso LA, Lemos-Senna E, Rafacho A

Endocrine2 Apr 2025Cited by 1 (Europe PMC)

PMID40169506 (opens in a new tab)DOI10.1007/s12020-025-04220-z (opens in a new tab)PepBankPUB-40169506
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intraperitoneal pramlintide produced an anorexigenic response at 200 µg/kg.

    In plain wordsIn mice, injected pramlintide reduced food intake.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseAcute food intake intraperitoneal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    200 µg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    In the refeeding test, the anorexigenic dose for the PRAM i.p. or LIRA i.p groups was 200 µg/kg and 400 µg/kg, respectively.
    1 context sentence
    Summary · context
    Adult male Swiss mice were submitted to a refeeding test in a dose-response study with intraperitoneal (PRAM i.p.) or intranasal (PRAM i.n.) pramlintide administration.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intraperitoneal liraglutide produced an anorexigenic response at 400 µg/kg.

    In plain wordsIn mice, injected liraglutide reduced food intake.

    Peptide
    Liraglutide
    Outcome
    DecreaseAcute food intake
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    400 µg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    In the refeeding test, the anorexigenic dose for the PRAM i.p. or LIRA i.p groups was 200 µg/kg and 400 µg/kg, respectively.
    1 context sentence
    Summary · context
    Intraperitoneal liraglutide served as a positive control (LIRA).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intranasal pramlintide showed a trend toward reduced food intake.

    In plain wordsIn mice, nasal pramlintide showed a trend toward reduced food intake.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseAcute food intake intranasal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    200 µg/kg · intranasalAs given in this study (mouse).

    Source sentences

    Summary
    The PRAM i.n. group (200 µg/kg) exhibited a trend for that.
    1 context sentence
    Summary · context
    In the refeeding test, the anorexigenic dose for the PRAM i.p. or LIRA i.p groups was 200 µg/kg and 400 µg/kg, respectively.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intraperitoneal pramlintide reduced gastric emptying compared with vehicle.

    In plain wordsIn mice, injected pramlintide slowed stomach emptying compared with vehicle.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseGastric emptying intraperitoneal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The reduction in gastric emptying occurred for all treated groups compared with their respective controls (vehicle-treated).
    1 context sentence
    Summary · context
    Adult male Swiss mice were submitted to a refeeding test in a dose-response study with intraperitoneal (PRAM i.p.) or intranasal (PRAM i.n.) pramlintide administration.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intranasal pramlintide reduced gastric emptying compared with vehicle.

    In plain wordsIn mice, nasal pramlintide slowed stomach emptying compared with vehicle.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseGastric emptying intranasal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intranasalAs given in this study (mouse).

    Source sentences

    Summary
    The reduction in gastric emptying occurred for all treated groups compared with their respective controls (vehicle-treated).
    1 context sentence
    Summary · context
    Adult male Swiss mice were submitted to a refeeding test in a dose-response study with intraperitoneal (PRAM i.p.) or intranasal (PRAM i.n.) pramlintide administration.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, liraglutide reduced gastric emptying compared with vehicle.

    In plain wordsIn mice, liraglutide slowed stomach emptying compared with vehicle.

    Peptide
    Liraglutide
    Outcome
    DecreaseGastric emptying
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The reduction in gastric emptying occurred for all treated groups compared with their respective controls (vehicle-treated).
    1 context sentence
    Summary · context
    Intraperitoneal liraglutide served as a positive control (LIRA).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice, subchronic intraperitoneal pramlintide did not reduce body mass.

    In plain wordsIn mice, injected pramlintide did not reduce body weight during repeated treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeSubchronic body mass intraperitoneal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · intraperitoneal · 8 daysAs given in this study (mouse).

    Source sentences

    Summary
    Neither the PRAM i.p. nor the PRAM i.n. groups exhibited reduced body mass and food intake in the subchronic experiment.
    1 context sentence
    Summary · context
    We also evaluated an 8-day treatment (once daily) to determine food intake and body mass.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice, subchronic intranasal pramlintide did not reduce body mass.

    In plain wordsIn mice, nasal pramlintide did not reduce body weight during repeated treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeSubchronic body mass intranasal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · intranasal · 8 daysAs given in this study (mouse).

    Source sentences

    Summary
    Neither the PRAM i.p. nor the PRAM i.n. groups exhibited reduced body mass and food intake in the subchronic experiment.
    1 context sentence
    Summary · context
    We also evaluated an 8-day treatment (once daily) to determine food intake and body mass.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice, subchronic intraperitoneal pramlintide did not reduce food intake.

    In plain wordsIn mice, injected pramlintide did not reduce food intake during repeated treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeSubchronic food intake intraperitoneal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intraperitoneal · 8 daysAs given in this study (mouse).

    Source sentences

    Summary
    Neither the PRAM i.p. nor the PRAM i.n. groups exhibited reduced body mass and food intake in the subchronic experiment.
    1 context sentence
    Summary · context
    We also evaluated an 8-day treatment (once daily) to determine food intake and body mass.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In mice, subchronic intranasal pramlintide did not reduce food intake.

    In plain wordsIn mice, nasal pramlintide did not reduce food intake during repeated treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeSubchronic food intake intranasal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intranasal · 8 daysAs given in this study (mouse).

    Source sentences

    Summary
    Neither the PRAM i.p. nor the PRAM i.n. groups exhibited reduced body mass and food intake in the subchronic experiment.
    1 context sentence
    Summary · context
    We also evaluated an 8-day treatment (once daily) to determine food intake and body mass.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intraperitoneal pramlintide did not affect blood glucose.

    In plain wordsIn mice, injected pramlintide did not change blood sugar.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeBlood glucose intraperitoneal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    No impact on biochemical parameters was observed regardless of the route of pramlintide administration.
    1 context sentence
    Summary · context
    Blood glucose and plasma triacylglycerides were measured on the euthanasia day.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intranasal pramlintide did not affect blood glucose.

    In plain wordsIn mice, nasal pramlintide did not change blood sugar.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeBlood glucose intranasal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intranasalAs given in this study (mouse).

    Source sentences

    Summary
    No impact on biochemical parameters was observed regardless of the route of pramlintide administration.
    1 context sentence
    Summary · context
    Blood glucose and plasma triacylglycerides were measured on the euthanasia day.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intraperitoneal pramlintide did not affect plasma triacylglycerides.

    In plain wordsIn mice, injected pramlintide did not change measured blood fats.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changePlasma triacylglycerides intraperitoneal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    No impact on biochemical parameters was observed regardless of the route of pramlintide administration.
    1 context sentence
    Summary · context
    Blood glucose and plasma triacylglycerides were measured on the euthanasia day.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intranasal pramlintide did not affect plasma triacylglycerides.

    In plain wordsIn mice, nasal pramlintide did not change measured blood fats.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changePlasma triacylglycerides intranasal
    Study

    mousen: not reported in source

    Adult male Swiss mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · intranasalAs given in this study (mouse).

    Source sentences

    Summary
    No impact on biochemical parameters was observed regardless of the route of pramlintide administration.
    1 context sentence
    Summary · context
    Blood glucose and plasma triacylglycerides were measured on the euthanasia day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.